James Watson’s Personal Genome Published in Nature


By Kevin Davies

April 16, 2008 | Fifty-five years after James Watson co-authored the most famous paper in Nature magazine’s history -- the discovery of the DNA double helix with Francis Crick -- his genome sequence is also gracing the pages of the famous scientific journal.

Following months of extensive review and revision, Nature finally publishes the paper reporting the Watson’s personal genome, or “Project Jim” as it was known, this week. The sequencing itself was performed by 454 Life Sciences, part of Roche, led by its founder and past chairman, Jonathan Rothberg. The bioinformatics analysis was handled by scientists at the Baylor College of Medicine genome center, led by Director Richard Gibbs and bioinformatician David Wheeler.

Watson’s sequence becomes the second full human genome sequence to be published, following the publication of Craig Venter’s sequence last year. But whereas Venter’s genome took years of work using traditional Applied Biosystems sequencing instruments, costing a reputed $70 million, the Watson genome was sequenced in a couple of months early last year using the 454 GS FLX pyrosequencing instruments. 454 estimates the final cost to be between $1-2 million. “This is the first [human] genome sequenced by next-generation technologies,” the authors emphasize.

James Watson (left) receives a digital copy of his genome sequence from Jonathan Rothberg in May 2007.

Last May, Rothberg presented a digital copy of the raw sequence on a portable hard drive to Watson in a ceremony at Baylor College of Medicine. (Rothberg is no longer affiliated with 454/Roche.) Watson’s genome assembly – with the exception of one Alzheimer’s associated gene (APOE on chromosome 19) that was redacted at Watson’s behest -- has been publicly annotated and presented by Lincoln Stein at Cold Spring Harbor Laboratory.

The Nature paper details the highlights of Watson’s genome analysis. All told, more than 93 million DNA sequence traces, averaging about 250 bases in length, were assembled to produce the final sequence. Of those, more than 1 million did not correspond to the reference genome sequence, indicating there is much more genomic variation between individuals than previously thought. The 454 team also points out that its amplification procedure dispenses with bacteria, and thus leads to more even representation of the full genome.

The final tally of 24.5 billion bases provides more than seven-fold coverage of the genome. Wheeler and colleagues documented more than 3.3 million single nucleotide polymorphisms (SNPs), of which more than 10,000 alter the primary amino-acid sequence of proteins.

The paper contains a one-page box written by Baylor bioethicist Amy McGuire on the ethical considerations in handling and communicating this genetic and medical information with Dr. Watson.

Editor’s Note: Last year, Kevin Davies interviewed lead author David Wheeler on the sequencing of the Watson genome. See the full interview here.

Further Reading: Wheeler, D. et al. “The complete genome of an individual by massively parallel DNA sequencing.” Nature 452; April 17, 2008. doi:10.1038/nature06884

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

This Bio•IT World Briefing On “Next-Generation Sequencing,” underwritten by GenomeQuest, Inc.,
presents a selection of feature stories, interviews,commentaries, conference reports, and editorials on the emergence, opportunities, and challenges posed by high-throughput sequencing. Covered in this collection: the launch of new platforms from Applied Biosystems and Helicos; new applications of nextgen sequencing; the rise of personal genomics; and informatics solutions to vexing problem of managing the vast volumes of next-gen data. Download now



SGI's Meeting Today’s Computational Needs for Science

The quest to better understand disease mechanisms and find new treatments is driven by new laboratory technologies and ever-more sophisticated modeling and simulation efforts. As such, life sciences R&D investigations increasingly are relying on more powerful computing resources. The challenge is how to accommodate the broad mix of applications.

Addressing this issue, this paper produced by the Bio-IT World Custom Publishing Group discusses a new SGI Hybrid Computing Environment approach. It optimally uses shared memory systems, multi-processor clusters, and FPGAs to accelerate computational workflows.



sgi_protm

SGI's Supercharging Proteomics Discovery

The deeper study of proteins and their interactions can reveal scientific information once considered nearly untouchable to scientists and researchers. Today, unprecedented advancements in computing power are enabling the creation of mounds of proteomic based data along with the accompanying bottlenecks data can create.

Rather than just “simplify the experiment” to fit the computational resources an alternative is now available with the SGI Proteomics Appliance. This complimentary white paper, produced by the Bio-IT World Custom Publishing Group, looks at ways to use the Proteomic Appliance to handle the most intensive proteomics computing tasks facing science today.



Life Science Webcasts & Podcasts

Trade Commission of Spain

Spain’s Emerging Biotech Revolution

The biotechnology sector is growing 10 percent faster in Spain than it is in the U.S. Driven by a culture, government and private sector that are open-minded and optimistic, Spain-based companies are emerging as leaders in this dynamic field. Discover how your business can capitalize on creative solutions from Spain-based enterprises by learning about:

  • Trends and factors driving the growth of Spain’s biotechnology sector.
  • The Spanish government’s aggressive policies and incentive programs for biotechnology research.
  • Biotechnology spin-offs, bio-clusters and new research centers in Spain that are combining entrepreneurial spirit with larger-than-ever resources.
  • The strength of Spain’s biomedicine community, and how U.S. pharmaceutical companies are capitalizing on it.

Download Now


More Podcasts

Job Openings

Friedrich Miescher Institute for Biomedical Research - Part of the Novartis Research Foundation
Basel, Switzerland is looking for a Head of IT Systems & Infrastructure. You will manage a cutting-edge core server and network infrastructure, comprising Linux and Solaris, as well as a robust Windows and Macintosh environment. We look forward to receiving your application: [email protected]. click for more information

Lilly Singapore Center for Drug Discovery (LSCDD) - Associate Director of Informatics
Lead and mentor a strong team for the Bioinformatics group at the Integrative Computational Sciences (ICS) department at LSCDD towards the development of novel algorithms, data analysis methods and software tools for drug discovery. Work closely with the Software Engineering group at ICS, and collaborate with the Discovery IT organization in Europe and USA. For additional information, or to apply visit: LSCDD

Related Resources & Products

Next-Generation Sequencing: Scientific and Commercial Implications of the $1000 Genome
Next-Generation Sequencing: Scientific and Commercial Implications of the $1000 Genome
Beyond Genome 2008
Beyond Genome 2008
Genome-Based Biomarkers for Adverse Drug Effects, Patient enrichment and Prediction of Drug Response, and Their Incorporation Into Clinical Trial Design




For reprints and/or copyright permission, please contact RMS, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext 100 or via email to [email protected].